Cargando…

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

PURPOSE: A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer (NMIBC) refractory to or intolerant of bacillus Calmette–Guerin (BCG). Secondary objectives included evaluation of the sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalski, Mark, Entwistle, Joycelyn, Cizeau, Jeannick, Niforos, Demi, Loewen, Shauna, Chapman, Wendy, MacDonald, Glen C
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998804/ https://www.ncbi.nlm.nih.gov/pubmed/21151619 http://dx.doi.org/10.2147/DDDT.S14071

Ejemplares similares

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck
por: MacDonald, Glen C, et al.
Publicado: (2009)

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
por: Lv, Minghua, et al.
Publicado: (2015)

Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy
por: Hosseinian, Seyed-Ali, et al.
Publicado: (2018)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
por: Andersson, Y, et al.
Publicado: (2015)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

Expression of EpCAM in uveal melanoma
por: Odashiro, Danilo N, et al.
Publicado: (2006)

Biology and clinical relevance of EpCAM
por: Keller, Laura, et al.
Publicado: (2019)

EpCAM as Modulator of Tissue Plasticity
por: Fagotto, François
Publicado: (2020)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer
por: Joshua, Julie Mariam, et al.
Publicado: (2019)

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2015)

Current View on EpCAM Structural Biology
por: Gaber, Aljaž, et al.
Publicado: (2020)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
por: Chen, Serena H., et al.
Publicado: (2021)

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
por: Chantima, Warangkana, et al.
Publicado: (2017)

Correction to: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2020)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
por: Beta, Madhu, et al.
Publicado: (2014)

EpCAM proteolysis: new fragments with distinct functions?
por: Schnell, Ulrike, et al.
Publicado: (2013)

EpCAM and the biology of hepatic stem/progenitor cells
por: Dollé, Laurent, et al.
Publicado: (2014)

Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013)

Functions of EpCAM in physiological processes and diseases (Review)
por: Huang, Li, et al.
Publicado: (2018)

Revisiting the Roles of Pro-Metastatic EpCAM in Cancer
por: Mohtar, M. Aiman, et al.
Publicado: (2020)

Correction: EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
Publicado: (2015)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

Expression of EpCam and Villin in Barrett’s Esophagus and in Gastric Cardia
por: Anders, Mario, et al.
Publicado: (2008)

Selection and targeting of EpCAM protein by ssDNA aptamer
por: Alshaer, Walhan, et al.
Publicado: (2017)

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
por: Macdonald, Joanna, et al.
Publicado: (2018)

Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma
por: Zheng, Jingying, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

EpCAM tumor specificity and proteoform patterns in urothelial cancer
por: Dressler, Franz F., et al.
Publicado: (2023)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager
por: Bagheri, Andisheh, et al.
Publicado: (2022)

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
por: Spizzo, Gilbert, et al.
Publicado: (2011)

Initial activation of EpCAM cleavage via cell-to-cell contact
por: Denzel, Sabine, et al.
Publicado: (2009)

Effects of EpCAM overexpression on human breast cancer cell lines
por: Gostner, Johanna M, et al.
Publicado: (2011)

Mutation of EpCAM leads to intestinal barrier and ion transport dysfunction
por: Kozan, Philip A., et al.
Publicado: (2014)

Correction: Selection and targeting of EpCAM protein by ssDNA aptamer
por: Alshaer, Walhan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ab4o8gj9bt3cl61226qa3rj8ov